National Polio Surveillance Program (NPSP)
Poliovirus

- Causes descending flaccid paralysis
- Phases:
- Alimentary phase
- Lymphatic phase → cervical, mesenteric LN
- Viremic phase → blood
- Neural phase → spinal cord, brain
- 90% infections → asymptomatic/subclinical
Types of Polio Infection & Percentage of All Infections
Types | Percentage of all infections |
Inapparent infection | 90–95% |
Abortive infection (Self-limiting) | 4–8% |
Non-paralytic aseptic meningitis | 1% |
Paralytic polio | Rare |
Carrier Stage
- For 1 infected child
- Approx. 75 adult carriers
- Approx. 1000 child carriers
Clinical features
- Asymmetric involvement
- Most commonly affected muscle: Quadriceps
- Result in Hand knee gait
- D/t Quadriceps weakness
- Most common muscle with complete paralysis: Tibialis anterior
- Most common hand muscle involved: Opponens pollicis
- Neurology
- Pure motor paralysis
- No sensory loss
- Knee deformity (severe cases)
- Triple deformity
- Flexion
- Posterior subluxation
- External rotation
Polio Vaccine strains and adverse effects
Strains | EDA |
P1 | M/c/c of Epidemic |
P2 | VDPP |
P3 | VAPP |
OPV vs. IPV
Feature | Oral Polio Vaccine (OPV): ↳ P₁, P₃ | Inactivated Polio Vaccine (IPV): ↳ P₁, P₂, P₃ |
Strain | SABIN | SALK |
Type | Live | Killed |
Route | Oral | ID |
Immunity | Local & humoral (Blood) | Only humoral |
Use in epidemic | ⊕⊕ | ⊖⊖ |
A/w VDPV, VAPP | ↑↑ | ↓↓ (Safer) |
Vaccine-Derived Polio Virus (VDPV) vs.
Vaccine-Associated Paralytic Polio (VAPP)
Feature | Vaccine Derived Polio Virus (VDPV) | Vaccine Associated Paralytic Polio (VAPP) |
Cause | Viral mutation | Random host immune reaction |
Associated | OPV P₂ (m/c) | OPV P₃ (m/c) |
Transmission | ⊕⊕ (more dangerous) | −− |
Timeline in India
Eradication Dates & Locations of Last Cases in India
Date | ㅤ | Location of last case |
24 October 1999 | Eradication of P2 strain | Uttar Pradesh |
13 October 2010 | Eradication of P3 strain | Jharkhand |
13 January 2011 | Eradication of P1 strain | Howrah, West Bengal |
27 March 2014 | Polio-free India | ㅤ |
2015 | End Game Strategic Plan ↳ Introduction of fractional IPV (fIPV) ↳ 2 doses | All over India |
25th April 2016 | National switch day ↳ Trivalent OPV → Bivalent OPV (P1 & P3) | ㅤ |
1st January 2023 | Third dose fIPV | ㅤ |
- 9, 10, 11 → 14, 15, 16
- Note: P1 strain →most epidemics
- Bivalent OPV
- Pink colour liquid stored at -20°C.
- Most heat-sensitive vaccine.
Fractional IPV Schedule
Dose | Schedule | Dosage & Route | Sites |
1ˢᵗ dose | 6 weeks | 0.1 mL ID | Right upper arm |
2ⁿᵈ dose | 14 weeks | 0.1 mL ID | Right upper arm |
3ʳᵈ dose | 9 months | 0.1 mL ID | Left upper arm |
National Polio Surveillance Program
- Started in 1995 with pulse polio immunization
- ↑↑ Herd immunity
- Requires >65% coverage.
Surveillance
- Continuous monitoring
- With support/feedback
Acute Flaccid Paralysis (AFP) Surveillance
- Age group <15 years.
- Surveillance MO (SMO)
Investigation:
- Within 48 hours of AFP reporting
- 1ˢᵗ stool sample
- 2ⁿᵈ stool sample
- Gap: 24 hrs to 14 days of onset of AFP
- Reach Laboratory within 72 hours
- Quality:
- Temperature of 2-8°C by reverse cold chain
- (Carrier: Red)
- Quantity:
- >8g/Thumb size.
- Residual paralysis check:
- within 60 days of reporting.
Lab Diagnosis:
- Throat swab, rectal swab, fecal samples
- Isolation rare
- Sewage samples → epidemiological burden
Surveillance Indicators & Targets
Surveillance Indicators | Target |
Sensitivity of surveillance: ↳ Most important Impact indicator | • >1 AFP/lakh/year in age <15 years |
Completeness of case investigation ↳ Operational indicator | • >80% adequate stool sample collection. • Operation → investigation - collection |
Completeness of follow up | • >80% AFP cases should have residual paralysis check at 60 days |
Operation efficacy | • Stool sample should reach the laboratory within 72 hours of collection |
Note: Causes of AFP

- Poliomyelitis
- Guillain-Barré syndrome
- Traumatic neuritis
- Traumatic myelitis
- Enterovirus A71
National Program for Control of Blindness & Visual Impairment (NPCBVI)

Program Details
- Funding: Danish International Development Agency (DANIDA).
- Target: Blindness rate <0.25% in community by 2025
Terminology for Visual Impairment
Terminology | Visual acuity in the better eye with available/best possible correction |
Visual impairment | <6/18 |
Blindness | <3/60 |
Definitions of Blindness:
- Clinically:
- No perception of light.
- According to NPCBVI (As amended in 2017) and WHO:
- Visual acuity <3/60 in the better eye with best possible correction.
- OR
- Limitation of Visual field <10 degrees from centre of fixation
Terminology | Visual acuity in the better eye with available/best possible correction |
Visual impairment | <6/18 |
Blindness | <3/60 |
Term | Definition |
Blindness (BCVA/Pinhole) | Best corrected visual acuity <3/60 in better eye. |
Blindness (<3m from chart) | <3/60 in better eye with available correction |
Severe Visual Impairment (SVI) (kasera aduppikuka → from 6m to 3m) | 6/60 – 3/60 in better eye |
Moderate Visual Impairment (MVI) (18-60) | 6/18 – 6/60 in better eye |
Early Visual Impairment (EVI) (12→18) | 6/12 – 6/18 in better eye |
Functional Low Vision | 6/18 or visual field <10° from fovea + usable vision retained |
WHO ICD | NPCB | Visual Acuity | Correlate |
Low Vision | LESMA | ㅤ | ㅤ |
Category (1) | Low vision | 6/18 - 6/60 | Moderate Visual Impairment |
Category (2) | Economic blindness Work Vision | 6/60 - 3/60 | Severe Visual Impairment |
Blindness | ㅤ | ㅤ | ㅤ |
Category (3) | Social blindness Walk Vision | 3/60 - 1/60 | Blindness |
Category (4) | Manifest blindness | <1/60 - perceptions of light | Blindness |
Category (5) | Absolute blindness | No perceptions of light | Blindness |
Cataract Intervention in Community/Village/Population
Reach-In Approach
- NPCBVI program:
- Patient
- Taken in a mobile van To Base hospital
- Perform surgery, Post-op care
- Brought back To Community/Village.
- Note: Reach-out approach/ makeshift hospitals
- discontinued due to cataract surgery complications.

Strategy
Centres under NPCBVI Strategy



WHO ICD vs. NPCB

- Most Common (M/C) Causes:
- Blindness (India & Worldwide):
- Cataract
- Responsible for 66-67% (2/3ʳᵈ) of blindness.
- Visual Impairment (India):
- Cataract
- Ocular Morbidity:
- Uncorrected refractive error
- Preventable Blindness:
- Children: Vitamin A deficiency
- Adults: Cataract
Causes of Blindness:
Age Group | Blindness | Visual Impairment (<6/18) |
≥50 years | - Cataract (m/c) - Corneal opacity | - Cataract (m/c) - Refractive error |
0–49 years | - Non trachomatous Corneal opacity (m/c) - Amblyopia | - Refractive error (m/c) - Cataract |
ㅤ | COOA | CRRC |
Vision 2020
Overview
- Launched: 1999, Geneva
- Adopted in India: 2001, Goa
Aims
- Reduce blindness to 25 million by 2020
- Eliminate avoidable blindness
- Leading cause of childhood blindness that can be prevented?
- Vitamin A Deficiency
- Added later → Glaucoma
- In India, the recent addition to the Vision 20/20 program
- Refractive error and low vision
Diseases Covered
Region | Diseases |
India | - Cataract - Refractive errors - Childhood blindness - Trachoma (Endemic) - Glaucoma - Diabetic retinopathy - Corneal blindness |
Globally | - Cataract - Refractive errors - Childhood blindness - Trachoma (Endemic) - Onchocerciasis |
National Leprosy Eradication Programme (NLEP)
Hansen's disease


Program History
- 1955: Started leprosy control programme
- 1983: Started multi-drug therapy & NLEP
- MOHFW: Ministry of Health & Family Welfare
NLEP Essential Indicators, Target Rate & Rate in India
ㅤ | Essential Indicators | Target Rate | Rate in India |
1 | Prevalence rate | <1/10,000 population | 0.45 |
2 | Annual New Case Detection Rate ↳ Best for significance of the health system | <10/1 lakh population | 5.5 |
3 | Grade-2 Disability (G2D) ↳ Best for leprosy awareness. | <1/10 lakh population | 0.2 |
4 | Treatment completion Rate (TCR) ↳ as proxy cure rate | ㅤ | ㅤ |
- Vision: Leprosy mukt Bharat by 2027.
Leprosy Awareness Programme


- SPARSH: To ↓ leprosy discrimination
Newer Strategies
- Welfare allowance:
- Rs 8000–12,000 for reconstructive surgeries.
- Asha-Based Surveillance for Leprosy Suspects (ABSULS).
- Nikusth 2.0 launched:
- mobile applications for leprosy notification.
Vaccine
- M. indicus prani.
- Immunomodulator
- Mycobacterium indicus pranii (MIP) vaccine:
- Produced in India.
- For leprosy.
- MW vaccine: Old
NIDDCP & IDSP
National Iodine Deficiency Disorder Control Programme (NIDDCP)
- 1962: National goitre control programme
- 1992: NIDDCP

- Organization: At district level.
- Target: Goitre rate <5% in children.
Strategy

- Iodization of salt: Potassium iodate used
- Not potassium Iodide
- Ensured by salt commissioner under:
- Ministry of Commerce & Industry.
- Headquarters in Jaipur, Rajasthan.
- Levels
- At production: >30 ppm.
- At Consumer: >15 ppm.
Programme Indicators
Category | Indicator |
Process indicators | • Iodine in household salt • Process in house |
Principal impact indicators | • Epidemiological indicator • Urinary iodine excretion > 100 U/dl • Impact principal by urination |
Environmental iodine deficiency indicator | • ↓↓ Iodine in diet • Neonatal hypothyroidism rate • Environment = Neonates |
Long term impact indicators | • Goitre rate • Long goitre |
Integrated Disease Surveillance Programme (IDSP)

- Started in 2004.
- Components
- Syndromic, Probable case, Laboratory case (SPL)
- Eye, ear, nose → For control of epidemic prone diseases.
- Weekly surveillance data reporting (52/year).
Integrated Health Intelligence Platform (IHIP)
- Newer version of IDSP.
- Under Central Bureau of Health Intelligence (CBHI).
Types of Surveillance
IDSP Types of Surveillance
Type | Syndromic | Probable | Laboratory |
Done by | Health workers | Medical officers | Laboratories |
Based on | Syndromes & field surveys 1. Fever 2. Cough <2 weeks 3. AFP <15 years age 4. Diarrhea ≥3 stool/day 5. Jaundice 6. Unusual death/hospitalization | • History & • Clinical examination | • Laboratory results |
NCD Programmes

National Programme for Prevention & Control of Non-Communicable Diseases (NP-NCD)
- Earlier term:
- National programme for prevention & control of
- cancer, diabetes, cardiovascular diseases & stroke.
- Prevention of: COPD, CKD, rheumatic fever, NAFLD.
- Integration with:
- AYUSH/NPCDCS.
- NTEP/NPCDCS.
Targets
- WHO Global action plan (Till 2030).
WHO Global Action Plan Targets for NCDs
Target (Relative Reduction) | Variable |
30% | Salt intake Smoking |
10% | Alcohol intake Physical inactivity |
25% (Outcome) | Premature mortality (CVD, Ca, DM, chronic respiratory disease) |
Obesity
- Indicators:
- Body mass index (BMI): m/c
- Quetelet index
- BMI = Weight (in kgs) / Height² (in metres)
- Ideal BMI (India): 18.5 – 22.9 kg/m ².
- Others: Broca’s index, corpulence index.
ㅤ | Reference male | Reference female (Non-pregnant) |
Weight (Kg) | 65 | 55 |
Age (years) | 19 to 39 | = |
Height (95th centile) | 1.77 m | 1.62 m |
BMI (Kg/m2) Normal: 18.5 to 22.9 | 20.75 | 20.95 |
Activity | • Occupation: 8 hours • Sleep: 8 hours • Sitting/moving around: 4 to 6 hours • Walking (Active recreation): 2 hours | ㅤ |
- Obesity cut-offs
Measure | Males | Females |
Waist circumference | <102 | <88 |
Waist hip ratio | <0.9 | <0.85 |
Skin fold thickness : ↳ Using herpenden's calliper (4 sites) | <40 mm | <50 mm |
Hypertension

- Rule of halves:
- 50% are diagnosed with HTN
- 50% on Rx
- 50% with controlled BP
- Tracking of blood pressure:
- Primary level prevention.
- Maintenance of normal BP from childhood onwards.
Cancer Registry

- Incidence in India:
- According to Globocan 2020,
- m/c in
- Males: Lip/oral > Lung > Stomach/oesophagus.
- Females: Breast > Cervix uteri > Ovary.
- Overall: Breast > Lip/oral > Cervix uteri.
- Female predominance.
- Mortality: Breast Ca > Cervical Ca.
WHO STEPS Approach

Used for: Surveillance of risk factors for Non-Communicable Diseases (NCDs)
Core Steps
Step | Component | Includes |
Step 1 | Questionnaire | Lifestyle, Behavioral, Psychological factors |
Step 2 | Anthropometric | Height, Weight, Waist & Hip circumference |
Step 3 | Biochemical | Blood glucose, Serum lipids |
Not included: Therapeutic interventions

School Health & POSHAN

Vision screening
- 1 teacher /150 students
- If < 6/9 → refer to PHC
- Ma() Le() ria - 25
1. School Health Services/Programme
- In charge:
- Medical officer of PHC (Under MOHFW)
School Health Service Criteria

Land | Classroom | Toilets |
Primary school: >5 acres Higher secondary school: >10 acres | Capacity: maximum of 40 students Space: minimum of 10 sq. Ft. per student Color of walls: white Light: Preferably shines from left side Desk: minus type | Urinal: 1/60 students Latrine: 1/100 students Separate for boys & girls |
Initiatives:
- Screening:
- Diseases (32 under RBSK).
- Mental health disorders.
- Vit A deficiency.
- Supplements:
- Weekly iron & folic acid.
- Menstrual hygiene:
- Free sanitary pads.
POSHAN x 2
POSHAN Abhiyaan

- Prime Minister Overarching Scheme for Holistic Nourishment (2018).
- Abhi - overacting
- Under Ministry of Women & Child Development (WCD).
- Integrated with
- National nutrition mission.
- Anemia mukt Bharat.
- Target: SULA
- ↓ Anemia prevalence by 3% per year.
- ↓ Low birth weight by 2% per year.
- Nutritional status improvement
- Children (0-6 years).
- Adolescent, Pregnant & lactating females.
Poshan Shakti Nirman Scheme (2021)
- Mid-day meal scheme under Ministry of Education.
- 1/2 protein and 1/3 calorie requirements
- Beneficiaries: Balvatika (<Class I) + Class I-VIII students.
ㅤ | For primary classes | For upper primary classes |
Calorie | 450 | 700 |
Proteins (g) | 12 | 20 |




Integrated Child Development Services (ICDS) Scheme


- Under Ministry of Women & Child Development (MoWCD).
- Beneficiaries:
- Children: 0 to 6 years.
- Adolescent girls: 10 to 19 years.
- Women of reproductive age: 15 to 49 years.
- Pregnant & lactating women.
- All females except 6-10 years and over 50 years
- Male only upto 6 years
- Note:
- National Health Mission → Ministry of health and family welfare
- ICDS →MoWCD
Structure:
- Anganwadi:
- Population 500 to 800.
- Single best ans: 800
- Anganwadi supervisor:
- Supervise 25 - 30 anganwadi
- Population 25,000.
- CDPO (Child Development Project Officer):
- Population 1,00,000.